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Abstract
Summary Assessment and treatment pathways based on age-specific intervention thresholds in Singapore using FRAX paths can
be used to identify patients at high risk of fracture and avoid unnecessary treatment in those at low risk.
Purpose Intervention thresholds for the treatment of osteoporosis have been based historically on the measurement of bone
mineral density. The development of FRAX® has permitted a more accurate assessment of fracture risk. The aim of the present
study was to explore treatment paths and characteristics of women selected for treatment in Singapore based on FRAX.
Methods The approach to the setting of intervention and assessment thresholds used the methodology adopted by the National
Osteoporosis Guideline Group for FRAX-based guidelines in the UK but based on the epidemiology of fracture and death in
Singapore. The methodology was applied to women age 50 years or more drawn from the population-based Singapore Chinese
Health Study (SCHS) cohort. Missing data for the calculation of FRAX was simulated using data from Chinese cohorts from
Hong Kong.
Results Intervention thresholds expressed as a 10-year probability of a major osteoporotic fracture ranged from 2.9% at the age of
50 years increasing to 32% at the age of 90 years. A total of 1927 of 29,323 women (7%) had a prior fragility fracture and would
be eligible for treatment for this reason. An additional 3019 women (10.3%) would be eligible for treatment on the basis of age-
dependent thresholds. The mean BMD T-score of women so selected was −2.94.
Conclusion Probability-based assessment of fracture risk using age-specific intervention thresholds was developed for Singapore
to help guide decisions about treatment.
Keywords Osteoporosis . Fracture risk assessment . FRAX . Intervention threshold
* John A. Kanis
w.j.Pontefract@shef.ac.uk
Manju Chandran
manju.chandran@singhealth.com.sg
Siok Bee Chionh
mdccsb@nus.edu.sg
Ganga Ganeson
Ganga_GANESAN@moh.gov.sg
Nicholas C Harvey
nch@mrc.soton.ac.uk
Woon-Puay Koh
woonpuay.koh@duke-nus.edu.sg
Timothy Kwok
tkwok@cuhk.edu.hk
Tang Ching Lau
mdcltc@nus.edu.sg
Enwu Liu
Enwu.Liu@acu.edu.au
Mattias Lorentzon
mattias.lorentzon@medic.gu.se
Eugene V McCloskey
e.v.mccloskey@sheffield.ac.uk
Kelvin Bryan Tan
Kelvin_Bryan_TAN@moh.gov.s
Liesbeth Vandenput
liesbeth.vandenput@medic.gu.se
Helena Johansson
helena@statiq.se
Extended author information available on the last page of the article
Archives of Osteoporosis          (2020) 15:104 
https://doi.org/10.1007/s11657-020-00782-9
Introduction
Osteoporosis is a common, chronic, and costly condition; the
annual economic burden in Singapore associatedwith fragility
fractures was estimated at approximately € 118 million in
2017 and is forecast to increase to € 186.9 million by 2035
[1]. In Europe, the annual cost of fractures associated with
osteoporosis exceeded € 37 billion in 2010 [2]. Disability
due to fragility fractures was greater than that caused by any
single cancer, with the exception of lung cancer and was com-
parable or greater than that caused by a variety of chronic
noncommunicable diseases, such as rheumatoid arthritis-,
asthma-, or high blood pressure-related heart disease [3].
Fortunately, a wide range of treatments is available that im-
prove bone mass and decrease the risk of fractures associated
with osteoporosis [4]. The use of such interventions by
healthcare practitioners is assisted by instruments that assess
patients’ fracture risk to optimize clinical decisions about pre-
vention and treatment. The most widely used web-based tool
FRAX® (https://www.sheffield.ac.uk/FRAX/) meets these
requirements and computes the 10-year probability of fragility
fractures based on several common clinical risk factors and,
optionally, a bone densitometry result obtained from dual x-
ray absorptiometry (DXA) [5, 6]. FRAX models are available
for 66 countries covering more than 80% of the world popu-
lation at risk [7] and have been incorporated into more than
100 guidelines worldwide [8].
A country-specific FRAX model was developed for
Singapore which was launched in December 2010. Whereas
the model should enhance accuracy of determining fracture
probability among the Singaporean population, guidance is
not yet available to make decisions about treatment [9]. The
aim of the present study was to explore a potential assessment
pathway for treatment and characteristics of women selected
for treatment in Singapore based on FRAX.
Methods
Population sample
The population sample used to determine the impact of inter-
vention and assessment thresholds was drawn from the
Singapore Chinese Health Study (SCHS). Details of the study
cohort have been previously described [10, 11]. In brief, the
cohort was recruited between 1993 and 1998, drawn from
permanent residents or citizens of Singapore who lived in
government-built housing (86% of the Singapore population
resided in such facilities at the time of recruitment, a propor-
tion that has remained stable over time). Men and women of
Chinese ethnicity age 45–74 years were eligible for inclusion.
A total of 63,257 persons (∼85% of eligible and invited sub-
jects) was enrolled. The present analysis was restricted to
women age 50 years or more at recruitment (n = 29,323).
Women were followed for an average of 9.1 years with a
maximum of 11.5 years, and incident hip fractures were
recorded.
Age and data on body mass index was available in all
women. With regard to the dichotomous FRAX variables,
information was available for prior fragility fracture (hip or
other bone fractures), current smoking, secondary osteoporo-
sis (prevalent type II diabetes only), and high alcohol intake (3
or more units per day). BMD values were not available nor
were a parental history of hip fracture, exposure to glucocor-
ticoids, and information on rheumatoid arthritis. For the pur-
poses of this analysis, these variables were simulated.
Simulation of Variables
Data from the Mr. and Ms. Os Hong Kong cohorts were used
to identify appropriate logistic regression equations needed to
generate data for the missing risk factors in the SCHS cohort
using methods described previously [12–14]. Mr. and Ms. OS
Hong Kong included Chinese men and women age 65 years
and older who were recruited between 2002 and 2003. The
cohort was age-stratified having 33% of subjects in each of the
following age groups: 65–69, 70–74, and > 75 years. Subjects
were recruited from housing estates and community centres
for the elderly. Participants had BMD measured using
Hologic QDR 4500 devices [15].
Logistic regression (for dichotomous risk factors) was used
to examine the conditional probability of the association of the
risk factor to be simulated for SCHS with age, sex, and body
mass index (BMI) as continuous variables and with previous
fracture, current smoking, and alcohol intake as dichotomous
variables. For family history of hip fracture, the associations
between the variable and age and previous fracture were used.
For glucocorticoid use, the associations between the variable
and age, sex and BMI were used. For rheumatoid arthritis, the
associations between the variable and sex, BMI and previous
fracture were used. Since the weight of the dichotomous clin-
ical risk factors is similar in men and women, the logistic
regressions were determined from Mr. and Ms. OS combined
to provide greater power to determine the logistic regressions
to be used.
The equations identified in the logistic regressions for the
dichotomous risk factors were then applied to the measured
risk factor data in the SCHS cohort to predict the likelihood of
having a positive value for the missing key risk factor for each
individual. Next, a random number was generated using a
computer programme, which was then compared with the
predicted likelihood for that variable for that individual. If
the random number was less than or equal to the predicted
probability, the woman was assigned a positive value for the
risk factor. If the random number was greater than the predict-
ed probability, the woman was assigned a negative value for
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the risk factor. In this way FRAX-based fracture probabilities
(without BMD) could be computed for the SCHS cohort. The
adequacy of the simulations was checked by comparing the
observed number of hip fractures with those predicted from
hip fracture probabilities computed by FRAX. In addition, the
prevalence of the simulated variables was compared with the
age-adjusted prevalence from Ms. Os.
The simulations for femoral neck BMD were based on
examining the conditional probability of the association of
BMD with risk factors, age, and BMI, by linear regression
[13]. For BMD, the associations between the variable and
age, BMI, previous fracture, and smoking were used. We
tested the validity of the simulation by computing the sensi-
tivity and specificity of the Osteoporosis Self-Assessment
Tool for Asians (OSTA) that is used in Singapore to identify
women with osteoporosis from height and weight [16]. We
additionally compared the age-matched BMD values in the
Ms. Os and simulated cohort.
Fracture Probabilities
The 10-year probabilities of hip fracture and a major osteopo-
rotic fracture (clinical spine, hip, humerus, or distal forearm
fracture) were calculated using the FRAX model for
Singapore (web version 4.1). Calculations were undertaken
with and without the inclusion of femoral neck BMD.
Intervention Thresholds Based on FRAX
The use of FRAX in clinical practice demands a consideration
of the fracture probability at which to intervene, both for treat-
ment (an intervention threshold) and for BMD testing (assess-
ment thresholds). The approach to the setting of intervention
and assessment thresholds used the methodology adopted by
the National Osteoporosis Guideline Group for FRAX-based
guidelines in the UK [17, 18].
A criterion for recommending intervention in women is a
history of a prior fragility fracture since many guidelines rec-
ommend that postmenopausal women with such an event may
be considered for intervention without the necessity for a
BMD test (other than to monitor treatment) [4, 8, 9, 18–22].
Given that a prior fragility fracture is considered to carry a
sufficient risk to recommend treatment, the intervention
threshold in women without a prior fragility fracture can be
set at the age-specific 10-year probability of a major osteopo-
rotic fracture (hip, spine, forearm, or humerus) equivalent to
women with a prior fragility fracture using the FRAX model
for Singapore. Body mass index was set at an ethnic- and age-
dependent value [23, 24].
The age-specific 10-year probability of a major osteoporot-
ic fracture equivalent to women with a prior fragility fracture
was calculated for each ethnicity in Singapore. Then an inter-
vention threshold was calculated using these probabilities
weighted by the ethnic-specific population of Singapore from
2017 at each 5-year interval from the age of 40 years [25]. The
setting of the intervention threshold differed from a previous
estimate by using age-specific data for the ethnic composition
of the population rather than a single estimate for all ages [24].
Assessment thresholds for BMD testing.
Two assessment thresholds for making recommendations for
the measurement of BMD were considered [17, 18]:
A threshold probability below which neither treatment
nor a BMD test should be considered (lower assessment
threshold).
A threshold probability above which treatment may be
recommended irrespective of BMD (upper assessment
threshold).
The lower assessment threshold was set to exclude a re-
quirement for BMD testing in women without clinical risk
factors, as given in current European guidelines [4, 19, 20].
It was therefore set to the age-specific 10-year probability of a
major fracture equivalent to women with no clinical risk fac-
tors. An upper threshold was chosen to minimize the proba-
bility that a patient, characterized to be at high risk using
clinical risk factors alone, would be reclassified to be at low
risk with additional information on BMD and vice versa [26].
The upper assessment threshold was set at 1.2 times the inter-
vention threshold as used in the UK [17].
Assessment strategy
As noted above, women with a prior fragility fracture were
considered to be eligible for treatment without the need for
further assessment. In women without a previous fragility
fracture, the management strategy was based on the assess-
ment of the 10-year probability of a major osteoporotic frac-
ture (clinical spine, hip, forearm, or humerus). Women with
probabilities below the lower assessment threshold were not
considered eligible for treatment. Women with probabilities
above the upper assessment threshold were eligible for treat-
ment. Women with probabilities between the upper and lower
assessment thresholds were to be referred for BMD measure-
ments and their fracture probability reassessed. On reassess-
ment of FRAX with the inclusion of femoral neck BMD,
individuals were considered eligible for treatment when frac-
ture probabilities lay above the intervention threshold.
Results
The baseline characteristics are given in Table 1. The preva-
lence of the simulated variables was similar to the age-
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matched prevalence of these risk factors from Ms. Os
(Table 4, Appendix A). Similarly, age-matched BMD values
in the SCHS cohort were similar to those in the Ms. Os cohort
(Table 5, Appendix A). In the SCHS cohort, the Osteoporosis
Self-Assessment Tool for Asians (OSTA) yielded a sensitivity
of 85% and specificity of 50% based on BMD at the femoral
neck.
Individual probabilities of hip fracture and a major osteo-
porotic fracture (with and without BMD) are given in Table 1.
The mean probability of a major fracture was 7.5% and, for a
hip fracture, was 2.8% when calculated without BMD.
Probabilities calculated with BMDwere similar. As expected,
average fracture probabilities increased progressively with
age. For a major osteoporotic fracture, the 10-year probability
rose from 2.1% in the age category 50–54 years to 24.3% for
the ages 80–84 years.
Hip fracture incidence was recorded during an average of
9.1 years with a maximum of 11.5 years of follow-up. During
this period with 266,025 person years of observation, 789
women experienced a first hip fracture (2.7%). FRAX-based
Table 1 Summary description of
the baseline variables in SCHS
cohort for women age 50 years or
more (N = 29,323)
N Mean SD n (%)
Age (years) 29,323 61.7 7.8
BMI (kg/m2) 29,323 23.2 3.6
Femoral neck BMD (T-score)2 29,323 −1.89 0.87
Previous fracture 29,323 1927 (6.6%)
Current smoking 29,323 1584 (5.4%)
Secondary osteoporosis 1 29,323 4228 (14.4%)
Alcohol 3 or more units per day 29,323 17 (0.0%)
Parental history of hip fracture2 29,323 1044 (6.6%)
Glucocorticoid exposure2 29,323 116 (0.4%)
Rheumatoid arthritis2 29,323 558 (1.9%)
Ten-year probability Range
Hip fracture probability calculated without BMD 2.8 4.0 0.1–70.1
Hip fracture probability calculated with BMD 3.0 4.7 0.1–76.0
MOF probability calculated without BMD 7.5 6.7 0.9–77.7
MOF probability calculated with BMD 8.0 7.3 0.9–77.8
1Type 2 diabetes
2 Simulated variable. MOF major osteoporotic fracture
Fig. 1 Number and cumulative
number of hip fractures expected
from categories of FRAX
measured at baseline and hip
fractures observed during follow-
up. Intervals are closed to the left,
(i.e. 0–1 = > 0–0.99, 1–2 = > 1–
1.99)
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hip fracture probabilities predicted 808 hip fractures. There
was a close correspondence between FRAX-based hip frac-
ture probability and observed hip fracture rates (Fig. 1).
Thresholds
The intervention threshold (set at the age-specific major oste-
oporotic fracture probability equivalent to women of average
BMI with a prior fragility fracture) rose with age from a 10-
year probability of 2.96% at the age of 50 years to 32% at the
age of 90 years (Table 2 and Fig. 2). Table 2 and Fig. 2 also
give the age-specific upper and lower assessment thresholds
for recommending the measurement of BMD in the assess-
ment of fracture probability. At the age of 65 years, for exam-
ple, a BMD test would not be recommended in an individual
with a fracture probability below 6.5%. At the same age, a
BMD test would be recommended with a fracture probability
that lay between 6.5 and 16%. Treatment would be recom-
mended without the requirement of a BMD test (for fracture
risk assessment, though possibly for monitoring of treatment)
in individuals with a fracture probability that exceeded 16%.
In individuals in whom a BMD test was undertaken and BMD
entered to the FRAX calculation, treatment would be recom-
mended in those with a fracture probability that was 13% or
greater.
Management pathway
One thousand nine hundred and twenty-seven of 29,323wom-
en (7%) had a prior fragility fracture and would be eligible for
treatment on this basis. For those without a prior fragility
fracture (n = 27,396), the outcome of risk assessment is shown
in Fig. 3. Of the whole cohort, 269 additional women (1%)
would be eligible for treatment in that their fracture probability
exceeded the upper assessment threshold for Singapore.
Table 2 Ten-year probability of a
major osteoporotic fracture (%)
by age at the intervention
threshold and lower and upper
assessment thresholds calculated
with FRAX for Singapore
adjusted for ethnicity
Age
(years)
Intervention thresholda
(%)
Lower assessment thresholdb
(%)
Upper assessment thresholdc
(%)
40 1.51 0.65 1.81
45 1.95 0.85 2.34
50 2.96 1.32 3.56
55 4.94 2.26 5.93
60 8.35 3.95 10.02
65 13.07 6.51 15.68
70 19.87 10.68 23.85
75 25.67 14.99 30.80
80 28.53 18.24 34.23
85 31.66 20.81 37.99
90 31.79 21.08 38.15
aThe threshold is the probability of a major osteoporotic fracture for a woman with a previous fracture and no
other clinical risk factors without BMD
bThe lower assessment is the probability of a major osteoporotic fracture for a woman with no clinical risk factors
without BMD
cThe upper assessment was set at 1.2 times the intervention threshold
Fig. 2 10-year probability (%) of a major osteoporotic fracture
corresponding to the lower assessment threshold (LAT) and upper
assessment threshold (UAT) for Singapore. The red area is where the
treatment would normally be recommended, the orange area shows the
limits of fracture probabilities for the assessment of BMD, and the green
area is where treatment would not normally be recommended
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Conversely, 9406 low risk women (32%) would not normally
be eligible for further assessment in that their fracture proba-
bility lay below the lower assessment threshold. The interme-
diate category of risk in Fig. 2 comprised of 17,721 women
(60%) in whom FRAX would be recalculated with the inclu-
sion of femoral neck BMD. With the inclusion of BMD,
14,971 women were categorized at low risk (51% of the total
cohort) and 2750 (9%) categorized at high risk. The overall
disposition of the cohort is shown in Table 3. Those identified
as eligible for treatment because of a prior fragility fracture or
for a high FRAX score had higher fracture probabilities than
those not eligible for treatment. The average 10-year fracture
probability (calculated without BMD) in all women identified
as eligible for treatment was 11.8 and 5.1% for major osteo-
porotic fracture and hip fracture, respectively.
Discussion
In this report, we present intervention thresholds and BMD
assessment thresholds based on fracture probability using
FRAX. The approach used was similar to that adopted by
the National Osteoporosis Guideline Group (NOGG) in the
UK and more recently in European guidelines [4, 6, 18] but
applied to the FRAXmodel for Singapore. Thus, the interven-
tion threshold was set at the fracture probability equivalent to
a woman from Singapore with a prior fragility fracture. The
rationale is that if women with a prior fragility fracture are
considered eligible for treatment, as commonly considered
and, indeed, recommended in the present Singapore guidance
[9], then women without fracture but with equivalent proba-
bilities should also be eligible for treatment. The use of a
Fig. 3 Management algorithm for
the assessment of individuals at
risk of fracture. The numbers in
each category of risk denote the
percentage of women in each
category
Table 3 Disposition of the Singaporean cohort according to NOGG guidance
Category Number % Mean BMD T-score Mean 10-year probability without
BMD (FRAX) (%)
Mean 10-year probability with
BMD (FRAX) (%)
MOF Hip MOF Hip
Entire cohort 29,323 100 −1.89 7.5 2.8 8.0 3.0
Treated (prior fragility fracture) 1927 6.6 −2.18 15.2 6.5 15.1 6.3
Otherwise eligible for treatment* 3019 10.3 −2.94 9.8 4.3 15.3 8.5
BMD tests 17,721 60.4 −1.98 7.7 2.9 8.2 3.2
No treatment 24,377 83.1 −1.74 6.6 2.3 6.5 2.0
*No prior fragility fracture but high FRAX score
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single intervention threshold, despite ethnic-specific FRAX
models, is appropriate in the sense that intervention is recom-
mended at an identical fracture probability irrespective of
ethnicity.
The starting point in the assessment of women is the pres-
ence of a clinical risk factor that alerts the physician to con-
sider osteoporosis. The opportunistic case finding strategy
arises because screening the general population is not widely
recommended in Asia or Europe, though advocated in North
America [12, 21]. In those eligible for assessment and in com-
mon with the NOGG guidelines, we limited the use of BMD
testing. Individuals with fracture probabilities equivalent to, or
lower than, those of women with no clinical risk factors (as
used in FRAX) would not be assessed by BMD. At the other
extreme, BMD testing was not universally recommended in
individuals at high risk. The rationale is that reclassification of
risk with the addition of a BMD test (from high risk to low risk
and vice versa) is high when fracture probabilities estimated
without BMD are close to the intervention threshold, but the
likelihood of reclassification decreases the further away the
probability estimate is from the intervention threshold [26].
The approach used has been well validated in the UK and
Canada [14, 26–29].
The attraction of this approach is that this makes efficient
use of BMD resources. The strategy implies, however, that
patients at high risk, but identified without BMD, would re-
spond to pharmacological intervention. The evidence that
such patients respond to treatment is strong [29–35]. A prin-
cipal reason is that BMD values are low in patients identified
with FRAX but without a BMD test [29]. Overall, the mean T-
score inwomen eligible for treatment and selectedwith FRAX
was −2.94 (see Table 3).
In the present study, we have focused on intervention
thresholds based on 10-year probabilities of a major osteopo-
rotic fracture. There is, in principle, no reason why a strategy
should not be based on the probability of hip fracture. Indeed,
screening on this basis has recently been shown to decrease
the incidence of hip fracture in the UK [36]. We have also
assumed that measurements of BMD are included in the strat-
egy. Where facilities for BMD testing are wanting, FRAX
without BMD provides similar predictive value as BMDwith-
out FRAX [37]. Nevertheless, the combination of FRAXwith
BMD where appropriate provides the optimal strategy.
The implementation of this strategy is expected to lessen
unnecessary treatment of individuals at low fracture risk and
better direct treatments to those at high risk than treatment
decisions based only on the measurement of BMD [37].
Implementation will, however, raise immediate problems in
that current guidance for treatment in Singapore, and many
other countries, is led by measurement of BMD. For example,
patients are eligible for treatment with a T-score of −2.5 SD or
lower. Thus, it will be important that healthcare agencies are
involved in any implementation process.
There are a number of potential limitations of the present
study to consider. First, although the cohort was large, it may
not be representative of the Singaporean population. A recruit-
ment bias towards healthier individuals is expected to prefer-
entially lower fracture probabilities when BMD is included in
the FRAX calculation. It is of interest that fracture probabili-
ties were very similar when calculated with or without BMD,
supporting a view that such bias is likely to be small. A more
robust argument that biases were small was the close agree-
ment between hip fracture incidence in the SCHS cohort and
that predicted from the Singaporean FRAX model.
Unfortunately, other outcome fractures were not available
from the SCHS cohort to check the predictive value of prob-
ability estimates of a major osteoporotic fracture. Another
important limitation was that not all FRAX variables were
documented in the SCHS cohort and the missing values were
simulated using regression equations derived from a Chinese
cohort in Hong Kong. The adequacy of the simulations is
supported by the similar prevalence of clinical risk factors in
the Hong Kong and SCHS cohorts. Moreover, we tested the
validity of the simulation of BMD by computing the sensitiv-
ity and specificity of OSTA. The sensitivity of 85% and spec-
ificity of 50% were very comparable with published estimates
of 91 and 45%, respectively [16]. Meta-analyses of studies
evaluating OSTA in Caucasian populations using the same
cut off threshold of < 1 to identify postmenopausal women
with osteoporosis at the femoral neck provided summary sen-
sitivity and specificity estimates of 89% (95%CI 82–96%) and
41 (95%CI 23–59%), respectively [38]. These considerations
suggest that the SCHS cohort was representative of the
Singaporean population and that the treatment pathways are
applicable to the general population.
The present study has shown that it is possible to apply
FRAX-based assessment guidelines using the same principles
that have been applied to guidelines elsewhere but tailored to
the epidemiology of Singapore. The approach to intervention
thresholds is based on the principles of case finding and does
not consider a health economic perspective. Although the ap-
proach has been shown to be cost-effective in a UK setting
[39], cost-effectiveness will necessarily differ in the context of
Singapore because of different fracture risks and costs. It will
be important therefore to underpin these guidelines with an
economic assessment. Overcoming these hurdles will, how-
ever, improve the delivery of healthcare to those most at need.
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Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons licence, and indicate if
changes weremade. The images or other third party material in this article
are included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in the
article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Table 4 The prevalence of the
simulated risk factors for SCHS
compared with the age-matched
prevalence from Ms. Os
Women in SCHS Women in Ms. Os
N Percentage (%) N Percentage (%)
Age 65–69
Family history of hip fracture 4687 6 565 8
Corticosteroid use 4687 0 669 0
Rheumatoid arthritis 4687 2 669 2
Age 70–74
Family history of hip fracture 3371 5 542 6
Corticosteroid use 3371 0 664 0
Rheumatoid arthritis 3371 2 665 2
Age 75–79
Family history of hip fracture 1905 3 354 2
Corticosteroid use 1905 0 449 0
Rheumatoid arthritis 1905 2 449 2
Age 80–84
Family history of hip fracture 257 2 125 2
Corticosteroid use 257 0 159 1
Rheumatoid arthritis 257 2 159 1
Table 5 Mean femoral neck BMD T-score and standard deviation (SD)
by age for SCHS compared with Ms. Os
Women in SCHS Women in Ms. Os
n Mean SD n Mean SD
Age 65–69 4687 −2.1 0.8 669 −2.0 0.8
Age 70–74 3371 −2.3 0.8 665 −2.3 0.8
Age 75–79 1905 −2.6 0.8 449 −2.5 0.8
Age 80–84 257 −2.7 0.9 159 −2.8 0.8
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